Roche Zenapax/CellCept combo trial to seek superiority to cyclosporine, PDL says.
Executive Summary
ROCHE CELLCEPT/ZENAPAX STUDY BEING TOUTED AS "CYCLOSPORINE ELIMINATION" TRIAL, Zenapax innovator Protein Design Labs President Jon Saxe told analysts at a Paine Webber meeting in New York June 4. Roche has "initiated very recently a study of CellCept [mycophenylate mofetil] and Zenapax [dacliximab] versus cyclosporine with the thought that you could replace cyclosporine with this combination, get at least a result with far better patient safety" without the nephrotoxicity of cyclosporine.